| Cell Therapy News 19.37 November 5, 2018 | |
|
|
|
|
TOP STORYSafe and Effective Superoxide Dismutase 1 Silencing Using Artificial MicroRNA in Macaques Scientists investigated silencing of SOD1, a gene commonly mutated in familial amyotrophic lateral sclerosis, using an adeno-associated virus encoding an artificial miRNA that targeted SOD1. [Sci Transl Med] Abstract |
|
|
|
|
PUBLICATIONS(Ranked by impact factor of the journal)Investigators demonstrated that their laminin system was comparable to the 3T3-J2 co-culture system in terms of basal markers’ profile, colony-forming efficiency and the ability to form normal stratified epidermal structure in both in vitro and in vivo models. [Nat Commun] Full Article | Press Release Cell Engineering with Microfluidic Squeezing Preserves Functionality of Primary Immune Cells In Vivo In a direct comparison of functionality, T cells edited for PD-1 via electroporation failed to distinguish from untreated controls in a therapeutic tumor model, while T cells edited with similar efficiency via cell squeezing demonstrated the expected tumor-killing advantage. [Proc Natl Acad Sci USA] Full Article | Editorial Switchable Control over In Vivo CAR T Expansion, B Cell Depletion, and Induction of Memory Researchers generated and assessed different murine switchable chimeric antigen receptor (sCAR) constructs to determine the factors that afford efficacy, persistence, and expansion of sCAR T cells in a competent immune system. They found that sCAR T cells underwent significant in vivo expansion, which is correlated with potent antitumor efficacy. [Proc Natl Acad Sci USA] Full Article Adjuvant Role of Macrophages in Stem Cell-Induced Cardiac Repair in Rats Myocardial infarction was induced in rats. One group was injected with bone marrow-derived mesenchymal stem cells (BMMSCs), and a second group was injected with MIX (a mixture of BMMSCs and bone marrow-derived macrophages after coculture). The reduction in cardiac fibrosis was greater in the MIX group than in the BMC group. [Exp Mol Med] Full Article WISP-1 Drives Bone Formation at the Expense of Fat Formation in Human Perivascular Stem Cells Scientists observed high expression of WISP-1 among human perivascular stem/stromal cells in vivo, after purification, and upon transplantation in a bone defect. [Sci Rep] Full Article The authors developed an engineered stem cell therapy product designed to treat critical limb ischemia that can be used in trauma-induced scarring and fibrosis where additional collateral blood flow is needed following damage to and blockage of the primary vessels. [Transfusion] Abstract Researchers genetically modified mesenchymal stem cells with growth arrest-specific gene 6 and evaluated cell survival, cardiac function, and infarct size in a rat model of myocardial infarction via intramyocardial delivery. [Arch Biochem Biophys] Abstract Investigators generated adeno-associated virus encoding artificial microRNA targeting human mutant torsinA and delivered them to the striatum of symptomatic transgenic rats that express the full human TOR1A mutant gene. [Brain Res] Abstract Researchers successfully delivered the knock-in donor DNA into zygotes by adeno-associated virus without removing the zona pellucida, and they succeeded in both large DNA fragment knock-in and whole exon exchange with electroporation of CRISPR/Cas9 ribonucleoprotein. [iScience] Abstract | Full Article | Graphical Abstract The authors investigated whether mesenchymal stem cell (MSC)-based treatment could inhibit neointimal hyperplasia in a rat model of carotid arterial injury and explored potential mechanisms underlying the positive effects of MSC therapy on vascular remodeling/repair. [Biochem Biophys Rep] Full Article Subscribe to one of our other 19 science newsletters such as Mesenchymal Cell News & ESC & iPSC News. |
|
|
|
|
REVIEWSScientists summarize the available clinical studies and basic research related to stem cell therapy for osteonecrosis of the femoral head. [Stem Cell Res Ther] Full Article Visit our reviews page to see a complete list of reviews in the cell therapy research field. |
|
|
|
|
SCIENCE NEWSUnum Therapeutics Inc. announced that the company will present preliminary results from the ongoing Phase I ATTCK-20-03 study, testing ACTR707 in combination with rituximab in patients with relapsed/refractory CD20+ B cell lymphoma, and the ongoing Phase I ATTCK-17-01 study, testing ACTR087 in combination with SEA-BCMA in patients with relapsed/refractory multiple myeloma. [Press release from Unum Therapeutics Inc. discussing research to be presented at the 2018 American Society of Hematology (ASH) Meeting, San Diego] Press Release Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program Allogene Therapeutics, Inc. announced that it will present data supporting its allogeneic pipeline program. [Press release from Allogene Therapeutics, Inc. discussing research to be presented at the 2018 American Society of Hematology (ASH) Meeting, San Diego] Press Release Gamida Cell Announces New Translational Data for Nicord® to Be Presented Gamida Cell Ltd. announced that new translational data for NiCord®, an investigational cell therapy in Phase III clinical development for allogeneic stem cell, or bone marrow, transplant, will be presented. [Press release from Gamida Cell Ltd. discussing research to be presented at the 2018 American Society of Hematology (ASH) Meeting, San Diego] Press Release Atara Biotherapeutics, Inc. announced data presentations that highlight the company’s robust off-the-shelf, allogeneic T-cell immunotherapy pipeline and next-generation CAR T technologies. [Press release from Atara Biotherapeutics, Inc. (GlobeNewswire, Inc.) discussing research to be presented at the 2018 American Society of Hematology (ASH) Meeting, San Diego] Press Release |
|
|
|
|
INDUSTRY NEWSNEC Corporation and Transgene announced the signing of a Memorandum of Understanding for a strategic collaboration aimed at the treatment of solid cancers. [NEC Corporation] Press Release CellProThera® and BioCardia® announced an agreement to expand their current collaboration to the SIngXpand Clinical Trial in Singapore. [BioCardia, Inc.] Press Release Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants. [City of Hope] Press Release Switzerland-Wide Platform for Cell Therapy Launched in Bern A national, public-private platform has been launched in Bern under the name “Translational and Clinical Bio-Manufacturing”. Its goal is to share expertise in the translation of research results into clinical application to promote Regenerative Medicine as well as new cell therapy approaches in Switzerland. [University of Bern] Press Release City of Hope, TGen Announce Letter of Intent to Build Cell Therapy Manufacturing Facility in Phoenix City of Hope and its affiliate, Translational Genomics Research Institute (TGen), have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area, a move that would improve the speed at which stem cell research and cancer treatment is delivered. [TGen] Press Release Histogenics Corporation provided an update on the NeoCart regulatory pathway based on preliminary feedback from the Type C meeting held with the FDA. [Histogenics Corporation] Press Release Sorrento Therapeutics, Inc. announced that the first patients were dosed in a Phase I study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple myeloma patients at two clinical sites – University of Pennsylvania and Roger Williams Medical Center. [Sorrento Therapeutics, Inc.] Press Release Poseida Therapeutics Inc. announced the FDA has granted an RMAT designation to P-BCMA-101, Poseida’s lead CAR-T therapeutic candidate currently in a Phase I clinical trial for the treatment of patients with relapsed/refractory multiple myeloma. [Poseida Therapeutics Inc.] Press Release Abeona Therapeutics Inc. and REGENXBIO announced a license agreement to REGENXBIO’s NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A, Sanfilippo syndrome type B, Infantile Batten Disease, also known as neuronal ceroid lipofuscinosis type 1, and Juvenile Batten Disease, also known as neuronal ceroid lipofuscinosis type 3. [Abeona Therapeutics Inc.] Press Release | |
|
|
|
POLICY NEWSWellcome and Gates Join Bold European Open-Access Plan Two of the world’s largest biomedical research funders have backed a plan to make all papers resulting from work they fund open access on publication by 2020. On 5 November, the London-based Wellcome Trust and the Bill and Melinda Gates Foundation in Seattle, Washington, announced they were both endorsing ‘Plan S’, adding their weight to an initiative already backed by 13 research funders across Europe since its launch in September. [Nature News] Editorial NSF Suspends Program Allowing Graduate Fellows to Study Abroad The U.S. National Science Foundation (NSF) has halted a program that each year allows hundreds of the nation’s best graduate students to work with experts in another country. And the agency isn’t saying why—or whether the program will resume. [ScienceInsider] Editorial Record Number of Monkeys Being Used in U.S. Research The number of monkeys used in U.S. biomedical research reached an all-time high last year, according to data released in late September by the United States Department of Agriculture. [ScienceInsider] Editorial Drug Companies Try to Catch the Rising Wave of RNAi Medicines Less than two months after the FDA approved the first-ever drug that uses a Nobel-winning technique to mute disease-causing genes, the pharmaceutical industry is already looking for a piece of the next one. [STAT News] Editorial
|
|
REGULATORYFDAProduct Development in Hemophilia; Public Workshop (FR Doc. No:2018-23947) Notice
|
|
EVENTSNEW The American Society for Cell Biology (ASCB) Annual Meeting 2018 Visit our events page to see a complete list of events in the community.
|
|
JOB OPPORTUNITIESNEW Assistant Project Scientist – Hematology and Oncology (University of California, Davis) NEW Senior Research Officer – Therapies for Neurodegenerative Disorders (University of Edinburgh) Executive Director – Cell and Gene Medicine (Stanford University) Faculty Positions – Hematology and Oncology (University of California Davis) Lab Technologist – Cell Therapy (University of Maryland Medical Center) Quality Control Scientists/Analysts – Cell and Gene Therapy (GlaxoSmithKline) Open Rank Professor – Biopharmaceutical Discovery (University of Delaware) Assistant Professor – Biology (University of Delaware) Director – Clinical Development (California Institute for Biomedical Research) Faculty Position – Adoptive T Cell Therapy (Dana-Farber Cancer Institute)
Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
|
|
|
Have we missed an important article or publication in Cell Therapy News? Click here to submit! Comments or suggestions? Submit your feedback here. |
|
|

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News




